Malaria is an infectious disease caused by Plasmodium through the bite of female mosquitoes, posing a significant threat to global public health. Since 2000, humans have adopted various measures to prevent and control malaria, but due to the impact of COVID-19, the number of malaria cases has increased rather than decreased, making malaria vaccines one of the focal points for controlling the disease. The Plasmodium that infects humans mainly includes Plasmodium falciparum and Plasmodium vivax. The life cycle of Plasmodium includes the pre-erythrocytic stage, the blood stage, and the mosquito stage. Two vaccines, RTS,S/AS01E, and R21/Matrix-M, which have been pre-qualified by the World Health Organization to target the pre-erythrocytic proteins of Plasmodium falciparum. The clinical trial data show reduction in malaria mortality rates among children, and mass vaccination is currently underway in Africa. However, no malaria vaccines targeting other stages or antigens have yet entered phase III clinical trials. This article describes the hazards and prevention of malaria, summarizes malaria vaccines designed in recent years for the three stages of the Plasmodium life cycle: the pre-erythrocytic stage, the blood stage, and the mosquito stage, and demonstrates the challenges and ideas in the field of malaria vaccine research and development, aiming to provide some reference for the development of novel malaria vaccines.

Objective:To investigate the safety, feasibility and efficacy of trans-oral robotic surgery in the treatment of lingual thyroglossal duct cyst. Methods:The clinical data of 21 patients with lingual thyroglossal duct cyst underwent trans-oral robotic surgery from May 2017 to March 2025 were analyzed retrospectively. Results:The cysts in all 21 patients were successfully excised by trans-oral robotic surgery. The mean robotic set-up and exposure time, operation time, estimated intraoperative blood loss and recovery time for oral intake were （14.3±7.2） min （[range 5.0-32.0]min）, （17.0±8.4） min （range[6.0-36.0]min）, （8.4±5.9） mL （range[2.0-25.0]mL） and （2.1±2.2） days （range[0-7]days）, respectively. No patients required tracheostomy, and no severe postoperative complications occurred. The patients were followed up for 2 to 96 months, with median follow-up time of 47 months, and 1 recurrence was observed. Conclusion:Excision of lingual thyroglossal duct cyst by trans-oral robotic surgery is safe and feasible, with rapid recovery and low recurrence rate, which is worth popularizing in clinical practice.
Humans ; Thyroglossal Cyst/surgery* ; Robotic Surgical Procedures/methods* ; Retrospective Studies ; Female ; Male ; Adult ; Treatment Outcome ; Middle Aged ; Adolescent

OBJECTIVE: We aimed to understand the willingness and barriers to the acceptance of tuberculosis (TB) preventive treatment (TPT) among people with latent TB infection (LTBI) in China. METHODS: A multicenter cross-sectional study was conducted from May 18, 2023 to December 31, 2023 across 10 counties in China. According to a national technical guide, we included healthcare workers, students, teachers, and others occupations aged 15-65 years as our research participants. RESULTS: Overall, 17.0% (183/1,077) of participants accepted TPT. There were statistically significant differences in the acceptance rate of TPT among different sexes, ages, educational levels, and occupations ( P < 0.05). The main barriers to TPT acceptance were misconceptions that it had uncertain effects on prevention (57.8%, 517/894), and concerns about side effects (32.7%, 292/894). CONCLUSION An enhanced and comprehensive understanding of LTBI and TPT among people with LTBI is vital to further expand TPT in China. Moreover, targeted policies need to be developed to address barriers faced by different groups of people.
Humans ; China/epidemiology* ; Adult ; Male ; Female ; Cross-Sectional Studies ; Middle Aged ; Young Adult ; Adolescent ; Aged ; Latent Tuberculosis/prevention & control* ; Patient Acceptance of Health Care ; Tuberculosis/prevention & control* ; Antitubercular Agents/therapeutic use* ; Health Knowledge, Attitudes, Practice

Objective:To construct a clinical benefit evaluation model of medical equipment based on the combination weighting of game theory with cloud model,so as to improve the clinical service capability and operational quality of medical equipment. Methods:The game theory,combination weighting and cloud model were used to scientifically empower and comprehensively evaluate 13 clinical benefit evaluation indexes from 3 dimensions:direct input,direct output. and indirect benefits of medical equipment,and to develop corresponding equipment management strategies.. 47 large medical equipment in clinical use at Taizhou People's Hospital from 2022 to 2023 were selected,and the large medical equipment used in 2022 was subjected to subjective evaluation management. The equipment used in 2023 adopts a medical device clinical benefit evaluation model (referred to as model evaluation management) of game theory combination weighting and cloud model to carry out clinical benefit evaluation and management of the equipment. The clinical benefit,operation quality and management level of the two management methods were compared. Results:The effective management rate of medical equipment using the model evaluation management method was 63.83％(30/47),which was higher than that using the subjective evaluation management method,and the difference was statistically significant (x2=5.158,P<0.05). The average clinical risk rate,failure rate and detection failure rate of medical equipment using the model evaluation management method were (10.59±3.09)‰,(7.27±3.53)‰ and (12.06±2.43)‰,respectively,all of which were lower than those obtained through the subjective evaluation management method. The differences were statistically significant (Z=3.783,2.748,3.928,P<0.05). The assessment scores of medical equipment use managers on the ability of equipment use,maintenance,repair and planning using the model evaluation management method were (93.38±3.73) points,(94.05±3.14) points,(92.61±3.44) points and (94.88±2.50) points,respectively,which were higher than those obtained through the subjective evaluation management method. The differences were statistically significant (Z=2.718,3.036,3.039,3.929,P<0.05). Conclusion:The application of the clinical benefit evaluation model of medical equipment,which based on the game theory combination weighting and cloud model,can accurately evaluate the clinical benefit level of medical equipment,and improve the operation quality of the equipment,and enhance the management level of equipment.

Objective:To construct a clinical benefit evaluation model of medical equipment based on the combination weighting of game theory with cloud model,so as to improve the clinical service capability and operational quality of medical equipment. Methods:The game theory,combination weighting and cloud model were used to scientifically empower and comprehensively evaluate 13 clinical benefit evaluation indexes from 3 dimensions:direct input,direct output. and indirect benefits of medical equipment,and to develop corresponding equipment management strategies.. 47 large medical equipment in clinical use at Taizhou People's Hospital from 2022 to 2023 were selected,and the large medical equipment used in 2022 was subjected to subjective evaluation management. The equipment used in 2023 adopts a medical device clinical benefit evaluation model (referred to as model evaluation management) of game theory combination weighting and cloud model to carry out clinical benefit evaluation and management of the equipment. The clinical benefit,operation quality and management level of the two management methods were compared. Results:The effective management rate of medical equipment using the model evaluation management method was 63.83％(30/47),which was higher than that using the subjective evaluation management method,and the difference was statistically significant (x2=5.158,P<0.05). The average clinical risk rate,failure rate and detection failure rate of medical equipment using the model evaluation management method were (10.59±3.09)‰,(7.27±3.53)‰ and (12.06±2.43)‰,respectively,all of which were lower than those obtained through the subjective evaluation management method. The differences were statistically significant (Z=3.783,2.748,3.928,P<0.05). The assessment scores of medical equipment use managers on the ability of equipment use,maintenance,repair and planning using the model evaluation management method were (93.38±3.73) points,(94.05±3.14) points,(92.61±3.44) points and (94.88±2.50) points,respectively,which were higher than those obtained through the subjective evaluation management method. The differences were statistically significant (Z=2.718,3.036,3.039,3.929,P<0.05). Conclusion:The application of the clinical benefit evaluation model of medical equipment,which based on the game theory combination weighting and cloud model,can accurately evaluate the clinical benefit level of medical equipment,and improve the operation quality of the equipment,and enhance the management level of equipment.

With the change of coronavirus disease 2019 (COVID-19) prevention and control strategy in China, the number of COVID-19 cases has increased significantly recently, which has also brought new challenges to the perioperative risk control of thoracic surgery. This paper puts forward several suggestions, aiming to standardize the preoperative screening and evaluation during the COVID-19 period, strictly grasp the indications and timing of surgery, optimize the medical management process, individualize surgical decision-making, and minimize the risk of COVID-19 infection to surgery.

With the change of COVID-19 prevention and control strategy in China, the number of COVID-19 cases has increased significantly recently, which has also brought new challenges to the perioperative risk control of thoracic surgery. This paper puts forward several suggestions, aiming to standardize the preoperative screening and evaluation during the COVID-19 period, strictly grasp the indications and timing of surgery, optimize the medical management process, individualize surgical decision-making, and minimize the risk of COVID-19 infection to surgery.

BACKGROUND: Perioperative treatment has become an increasingly important aspect of the management of patients with non-small cell lung cancer (NSCLC). Small-scale clinical studies performed in recent years have shown improvements in the major pathological remission rate after neoadjuvant therapy, suggesting that it will soon become an important part of NSCLC treatment. Nevertheless, neoadjuvant immunotherapy may be accompanied by serious adverse reactions that lead to delay or cancelation of surgery, additional illness, and even death, and have therefore attracted much attention. The purpose of the clinical recommendations is to form a diagnosis and treatment plan suitable for the current domestic medical situation for the immune-related adverse event (irAE). METHODS: This recommendation is composed of experts in thoracic surgery, oncologists, thoracic medicine and irAE related departments (gastroenterology, respirology, cardiology, infectious medicine, hematology, endocrinology, rheumatology, neurology, dermatology, emergency section) to jointly complete the formulation. Experts make full reference to the irAE guidelines, large-scale clinical research data published by thoracic surgery, and the clinical experience of domestic doctors and publicly published cases, and repeated discussions in multiple disciplines to form this recommendation for perioperative irAE. RESULTS: This clinical recommendation covers the whole process of prevention, evaluation, examination, treatment and monitoring related to irAE, so as to guide the clinical work comprehensively and effectively. CONCLUSIONS Perioperative irAE management is an important part of immune perioperative treatment of lung cancer. With the continuous development of immune perioperative treatment, more research is needed in the future to optimize the diagnosis and treatment of perioperative irAE.

Objective:To investigate the efficacy and safety of surgery via endoscopic-assisted transcallosal approach in intraventricular hemorrhage (IVH).Methods:A retrospective study was performed; the clinical data of 68 IVH patients admitted to our hospital from October 2016 to January 2020 were analyzed. These patients were divided into endoscopic treatment group ( n=34) and drainage group ( n=34) according to the treatment methods. In the endoscopic treatment group, IVH was evacuated via endoscopic-assisted transcallosal approach; in the drainage group, external ventricular drainage and urokinase injection were performed. Gross hematoma clearance rate (clearance rate≥95%) 1, 3, and 7 d after surgery, complication incidence 7 d and 1 month after surgery, and good prognosis rate (ability of daily living [ADL] grading I-III) 3 months after surgery were compared between the two groups. Results:One, 3, and 7 d after surgery, the gross hematoma clearance rate in the endoscopic treatment group was significantly higher than that in the drainage group ( P<0.05). The recurrent hemorrhage rate within 7 d of surgery, intracranial infection rate, and percentage of patients with secondary hydrocephalus requiring shunt within 30 d of surgery in the endoscopic treatment group were significantly lower than those in the drainage group (2.9% vs. 20.6%, 2.9% vs. 23.5%, 5.9% vs. 17.6%, P<0.05). Three months after follow-up, the good prognosis rate of patients in the endoscopic treatment group was significantly higher than that in the drainage group (91.2% vs. 58.9%, P<0.05). Conclusion:Endoscopic-assisted transcallosal approach is recommended in clinical treatment of IVH, which can significantly reduce postoperative complications and improve postoperative prognosis.

Objective: To evaluate the indication, safety and effectiveness of transoral robotic surgery (TORS) for oropharyngeal cancer based on our preliminary experience. Methods: Twelve patients, including six with tonsil cancer, five with tongue base cancer and one with posterior pharyngeal wall cancer, who underwent TORS with Da Vinci Si surgical system from March 2017 to October 2018 at Tongji Hospital of Huazhong University of Science Technology were respectively analyzed. And the surgical time, intraoperative blood loss, postoperative local bleeding, dyspnea, nerve function injury, oral intake time, whether or not to receive chemoradiotherapy were analyzed. Results: All tumors in the 12 patients were en bloc removed by TORS. Surgical time ranged from 25 to 80 min with an average of 34.2 min. The blood loss ranged from 10 ml to 50 ml with an average of 20.8 ml. The recovery time for oral intake ranged from 1 day to 30 days with an average of 8.4 days. No patient underwent tracheostomy after TORS. Also, no patient manifested with airway obstruction, bleeding or nerve injury symptoms after operation. All 12 patients reached pathologically negative surgical margins. The patients were followed up for 4 to 22 months, with a median of 12 months. All patients who combined with more advanced than T3 stage, or more advanced than N2 stage were recommended to oncologist, then, followed with radiotherapy or chemoradiotherapy if no relevant contradictions occurred. No local recurrence or distant metastasis case was found. Conclusion With proper indications, the application of TORS in oropharyngeal cancer is a relatively safe, effective and minimal invasive therapy, which merits more clinical applications.